CytoSorbents

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytoSorbents reports growth in treatments and sales despite margin challenges

CytoSorbents demonstrated strong performance in treatment deliveries and sales momentum, despite margin challenges.
The company's focus on R&D and regulatory expertise positions it well for future growth opportunities.
Operational improvements and market expansion efforts are key to overcoming current challenges and driving profitability.
With a favorable competitive position and strategic initiatives, CytoSorbents aims to capitalize on emerging market opportunities.

CytoSorbents reports robust Q1 performance and eyes market expansion

CytoSorbents demonstrated strong performance in Q1 2023 with notable revenue and treatment milestones, alongside strategic market expansion efforts.
While facing challenges such as declining gross margins and managing costs, the company is focused on leveraging opportunities for growth and profitability.
Overall, CytoSorbents' financial health, product advancements, and market strategies position it well for future success and market expansion.

CytoSorbents reports robust Q2 earnings, eyes U.S. market expansion

CytoSorbents' Q2 2023 performance reflects strong revenue growth, operational milestones, and strategic partnerships driving future expansion.
While facing challenges in managing cash burn and regulatory hurdles, the company is well-positioned to capitalize on market opportunities.
With a focus on product innovation, market expansion, and financial sustainability, CytoSorbents aims to drive continued growth and market success.

CytoSorbents excels in Q3, eyes FDA approval and market expansion

CytoSorbents reported strong financial performance in Q3 2023, with revenue growth and a robust gross margin.
The company's focus on critical care markets and progress in the STAR-T trial indicate promising growth potential.
Challenges lie in maintaining cash reserves, securing FDA approvals, and navigating market competition.
Opportunities include expanding product portfolio, exploring capital sources, and leveraging favorable market conditions in Canada.

CytoSorb reports revenue growth and margin improvement in 2023

CytoSorb showed solid performance in 2023 with revenue growth and margin improvement.
Strategic partnerships and government support position the company for future growth.
Challenges include distributor order delays and market uncertainties in Germany.
Opportunities lie in new product initiatives, regulatory submissions, and international expansion.

CytoSorbents reports robust Q1 performance, eyes FDA submissions for growth

CytoSorbents delivered strong financial and operational performance in Q1 2024, driven by revenue growth and improved margins.
While facing challenges such as lower grant income and the need to maintain consistent performance, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial prudence, CytoSorbents aims to sustain its positive momentum throughout the year.

CytoSorbents reports revenue growth and operational improvements in Q2 2024

CytoSorbents' Q2 2024 showed positive revenue growth, operational improvements, and strategic advancements.
The company's focus on financial stability, regulatory progress, and cost efficiency bodes well for future performance.
While challenges like operational losses and regulatory hurdles persist, opportunities for growth and optimization are evident.
Overall, CytoSorbents is positioned for continued growth and success with a solid financial foundation and strategic direction.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

Shares of CytoSorbents (NASDAQ:CTSO) fell 2.15% in after-market trading after the company reported Q2 results.

Recap: CytoSorbents Q2 Earnings

MONMOUTH JUNCTION, N.J., Aug. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its.

CytoSorbents Reports Record Second Quarter 2020 Financial Results

CytoSorbents (NASDAQ: CTSO) releases its next round of earnings this Tuesday, August 04.

Earnings Outlook for CytoSorbents

MONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces.

CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date

MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office.

CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients.

CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ -- CytoSorbents Corporation (CTSO), CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery.

CytoSorbents to Report Q2 2020 Operating and Financial Results

The company has priced its recently announced stock offering.

Why CytoSorbents Is Soaring 12% Today

MONMOUTH JUNCTION, N.J., July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac.

CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock

A stock offering overshadowed the company's impressive preliminary second-quarter results.

Why CytoSorbents Stock Got Clobbered Today

ACADIA Pharma

Genworth Financial

Hibbett Sports

Limelight Networks

New Age Beverages

Qiwi

Tonix Pharmaceuticals Hld

The S&P 500 closing up 0.8% at 2,251.84 and with the NASDAQ closing up 2.5% at 10,767.09, many investors are wondering how stocks keep rising despite the major recession in the time of a COVID-19 pandemic.

9 Stocks With Massive Moves in Monday’s After-Hours Session

MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provides.

CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update

MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company") a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac.

CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock

MONMOUTH JUNCTION, N.J., June 29, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces...

CytoSorbents to Host Key Opinion Leader Call on the Use of CytoSorb Blood Purification to Remove Antithrombotic Medications in Patients at Risk of Bleeding

MONMOUTH JUNCTION, N.J., June 24, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the...

CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise

MONMOUTH JUNCTION, N.J., June 9, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that it was awarded a Defense Health Agency Small Business Technology Transfer (STTR) Phase III contract,...

CytoSorbents Awarded $2,897,172 Phase III STTR Contract to Advance HemoDefend-BGA Plasma and Whole Blood Filter to Clinical Trials

Athersys

Chimerix

CytoDyn Inc.

Mesoblast

Below is a list of six companies with promising Covid-19 treatments in various stages of development, and the reasons why I have invested in them.

COVID-19 Therapeutics: The Leading Contenders

MONMOUTH JUNCTION, N.J., May 27, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients...

CytoSorbents Announces Virtual Annual Meeting

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2020 Results - Earnings Call Transcript

Cytosorbents: COVID-19 Has Presented A Bullish Opportunity

Shares of CytoSorbents Corp. CTSO, +28.52% gained 28.7% in trading on Monday following a Food and Drug Administration announcement late on Friday that grants an emergency use authorization to the company's blood purification system for COVID-19 patients.

CytoSorbents' stock jumps on FDA authorization for its device in COVID-19 patients

CytoSorbents Corporation (CTSO) CEO Phillip Chan on Q4 2019 Results - Earnings Call Transcript

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q3 2019 Results - Earnings Call Transcript

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q2 2019 Results - Earnings Call Transcript

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2019 Results - Earnings Call Transcript

News for CytoSorbents Stock (CTSO)